| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We performed a comprehensive genetic analysis for lung adenocarcinomas (LADC) and found that the driver fusion cases showed a distinct profile with smaller numbers of nonsynonymous mutations in cancer-related genes or truncating mutations in SWI/SNF chromatin remodeling. On the other hand, pan-negative LADCs appear to develop from a large number of gene mutations, including mutations in TP53 and other cancer-related genes. Next, we have compared the frequency of each driver genes between Japan and US cohort. EGFR mutations are more prevalent in Japanese patients, whereas KRAS and BRAF mutations are more prevalent in the US. To date, the molecularly targeted drugs for KRAS mutations have not developed yet, targeted therapy have not adapted the patients with LADC in the US. In conclusion, the information of driver genes will aid in the selection of appropriate targeted therapy.
|
